News

Alvotech Begins Trading on Nasdaq Stockholm: A New Era

Alvotech Begins Trading on Nasdaq Stockholm: A New Era

Alvotech Launches Trading on Nasdaq Stockholm

As of today, Alvotech (NASDAQ: ALVO) announces an exhilarating milestone: trading of its shares on Nasdaq Stockholm has officially commenced. This listing marks a significant step forward for the global biotech company, which is widely recognized for developing and producing biosimilar medicines for patients around the globe.

The recent public offering of Swedish Depository Receipts (SDRs) was met with substantial enthusiasm, reflecting the robust interest from the general public in Sweden. In fact, the offering was oversubscribed multiple times, showcasing investors’ strong confidence in Alvotech's future and growth potential.

Highlights of the Offering

The final Offering Price was set at SEK 87.51 per SDR, which corresponds to the average market price of Alvotech’s ordinary shares on Nasdaq Iceland during the application period. This pricing included a ten percent discount and was established using the exchange rates published by Sweden's central bank. During the application window from May 9 to 16, 2025, an impressive 441,600 SDRs were offered, each representing one ordinary share of Alvotech. The gross proceeds totaled around SEK 39 million.

Moreover, all 3,000+ individuals who subscribed for SDRs in this offering were allotted shares, emphasizing the broad-based interest in Alvotech’s market entrance under the ticker symbol “ALVO SDB”. Settlement for these transactions is expected to occur shortly.

Alvotech's Vision and Market Expansion

According to Róbert Wessman, Alvotech’s Founder, Chairman, and CEO, this listing on Nasdaq Stockholm is pivotal, allowing the company to better service current and future shareholders. "Our aim is to enhance market accessibility for our investors in the Nordic and European territories. Today is a thrilling new chapter for Alvotech as our shares are now traded across three major markets," he stated. This development is anticipated to improve share liquidity and broaden the company’s shareholder base significantly.

The company is focused on advancing its research and development (R&D) capabilities. The expansion strategy includes attracting seasoned life-science R&D professionals from outside Iceland, which will bolster Alvotech’s innovative efforts. Notably, the acquisition of Xbrane Biopharma AB’s operations at a recognized life-science hub in Sweden is a key move in integrating additional talented developers into Alvotech's workforce, thereby enhancing its scientific capabilities.

Strengthening European Presence

With the listing on Nasdaq Stockholm, Alvotech aims to strengthen its visibility within the Nordic and European markets, all while enhancing access to essential regional capital. Their strategy includes engaging with institutional and retail investors across various markets to widens their investment base significantly. Growing investor demand in the European biotechnology sector presents a promising opportunity for the firm.

Additionally, Alvotech has recognized the necessity for liquidity improvements and plans to enter agreements with market makers to facilitate trading volume for its newly listed SDRs.

Special Conversion Opportunities for Shareholders

In a beneficial move for existing shareholders, Alvotech will offer a unique free conversion period. This initiative allows previous shareholders to convert their unrestricted shares into SDRs without conversion fees during the first year of trading. This step is aimed at increasing the shareholder engagement in capitalizing on the SDRs during their early trading days.

For more information about the conversion process, shareholders can contact Alvotech’s designated email.

The Future of Alvotech

As a dedicated player in the biotechnology sphere, Alvotech prides itself on fostering high-quality, affordable biosimilar medicines catering to unique health needs. Their current portfolio includes two approved biosimilars, with a pipeline comprising nine additional candidates targeting a range of medical conditions including autoimmune disorders and cancer.

With established partnerships including Teva Pharmaceuticals and other notable firms, Alvotech is well-positioned for an expansive market reach, thereby contributing to its goal of becoming a leading force in the biosimilars market globally.

Frequently Asked Questions

What is the significance of Alvotech's listing on Nasdaq Stockholm?

The listing enables Alvotech to tap into a broader investor base and enhances share liquidity, supporting its growth ambitions in the biosimilars sector.

What was the outcome of the recent SDR offering?

The SDR offering was oversubscribed and raised approximately SEK 39 million, showing strong public interest in Alvotech's future endeavors.

How does Alvotech plan to expand its R&D capabilities?

The company aims to integrate Xbrane Biopharma's R&D operations, enhancing its scientific expertise and broadening its talent pool.

What are Alvotech's current products in the market?

Alvotech has two approved biosimilars for Humira (adalimumab) and Stelara (ustekinumab), targeting multiple global markets.

Who can convert shares to SDRs, and what are the fees involved?

Existing shareholders can convert their unrestricted shares to SDRs during the one-year free conversion period, with conversion fees covered by Alvotech, except any additional custodian costs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 99

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 460

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 737

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 67

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 354

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 200

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Clariant Adjusts Sales Targets Amidst Market Challenges

Updated Category News Views 179

Clariant Adjusts Its Sales Projections In recent trading, shares of Clariant (SIX: CLN) experienced a decline exceeding 5% as the Swiss chemicals giant updated its annual sales forecasts and announced third-quarter profits that fell short of market expectations. This adjustment raises questions about the current state of the chemical industry and Clariant's positioning...

Continue Reading
Growth and Future of the Vehicle Electrification Industry

Updated Category News Views 435

The Surge in Vehicle Electrification: A Market Overview The global Vehicle Electrification Market is set to witness remarkable growth, forecasted to expand from USD 51.84 billion to USD 83.87 billion by 2032, achieving a compound annual growth rate (CAGR) of 7.1%. As the world shifts towards sustainable mobility, electrification in vehicles is accelerating, transforming...

Continue Reading
Unlocking the Secrets of Grain Foods for a Healthier Life

Updated Category News Views 198

New Research Reveals Benefits of Grain Foods Recent studies have shed light on the vital role that grain foods play in achieving healthier diet patterns and metabolic health. This research highlights that a variety of grain foods can significantly contribute to improved nutrition, leading to better health outcomes for individuals. Grain foods, whether whole or refined,...

Continue Reading
Lands' End Adjusts Financial Outlook Amid Revenue Changes

Updated Category News Views 151

Lands' End Updates Financial Outlook Following Revenue Changes Lands’ End, Inc. (NASDAQ: LE) has seen its stock rise after the company announced its second-quarter earnings. While it faced some revenue challenges, it reported net revenue of $317.2 million, exceeding analyst predictions of $307.41 million. Overview of Quarterly Performance The adjusted loss per share was...

Continue Reading
California's Housing Affordability Experiences Minor Fluctuations

Updated Category News Views 127

Current Trends in Housing Affordability in California As of mid-2025, 15% of households in California can afford a median-priced home costing $905,680. This figure dropped from 17% in the previous quarter but showed improvement from 14% the same time last year. The Traditional Housing Affordability Index (HAI) indicates persistent affordability challenges for potential...

Continue Reading